Glaukos Corporation's SVP and Chief Financial Officer, Alex R. Thurman, reported multiple share disposals in late March. According to a Form 4 filed with the Securities and Exchange Commission, Thurman sold 1,521 shares of common stock on March 24 at a price of $105.24, generating proceeds of $160,070.
In addition to that sale, the filing shows Thurman transferred shares to cover tax obligations: 1,230 shares on March 23 and 2,020 shares on March 24. Those tax-related transactions were executed across prices ranging from $105.23 to $106.84 and together totaled $343,977.
After these moves, Thurman’s reported direct holdings stand at 44,478 shares of Glaukos stock. That total includes 5,230 restricted stock units that have not yet vested, as noted in the filing.
The March 24 disposition for 1,521 shares was carried out under a Rule 10b5-1 trading arrangement that the filing says was adopted on December 15, 2025. The filing does not provide additional detail about the plan beyond the adoption date and the trades executed under it.
Valuation context and analyst commentary
Investor research cited in the filing and related commentary points to varied views on Glaukos’ valuation and commercial trajectory. An InvestingPro analysis included in the materials characterizes the stock as appearing overvalued at current levels and reports analyst price targets ranging from $120 to $165. The same platform is referenced as offering eight additional ProTips for the ticker and a comprehensive Pro Research Report that frames Glaukos as a medical device company with a market position valued at $6.33 billion.
Independent sell-side coverage referenced around the company highlights continuing bullish sentiment from several firms. Piper Sandler reiterated an Overweight rating and a $165 price target, citing multiple pathways to meet fiscal 2026 revenue estimates. Stifel kept a Buy rating with a $160 price target and pointed to positive momentum for both the iDose and Epioxa product lines. Needham increased its price target slightly from $125 to $127 while maintaining a Buy rating, noting fourth-quarter 2025 revenue was in line with expectations and that iDose uptake is advancing.
Stifel’s commentary, as included in the reporting, suggests a favorable risk-reward profile for the company’s iDose franchise even when accounting for the possibility of Local Coverage Determination (LCD) restrictions on reimbursement or access.
Regulatory development
Separately noted in the filings and company commentary is a regulatory milestone: the U.S. Food and Drug Administration approved a New Drug Application labeling supplement for Glaukos’ iDose TR product. That approval permits re-administration of iDose TR in patients with a healthy cornea, enabling physicians to perform repeat treatments and thereby expanding clinical management options for some glaucoma patients. The filing materials tie this regulatory update to the broader narrative around the product’s market momentum.
Taken together, the insider share disposals, valuation commentary, analyst positioning, and the FDA labeling approval comprise the key elements investors and market participants are weighing as they assess Glaukos’ near-term commercial outlook and longer-term strategic prospects.